136 assets in B-Cell Acute Lymphoblastic Leukemia

Therapeutic assets addressing B-Cell Acute Lymphoblastic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
U-Car-T Cells B-Cell Acute Lymphoblastic Leukemia	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	P1/2	CC (43)
Vnx-101 B-Cell Acute Lymphoblastic Leukemia	Vironexis Biotherapeutics Inc.	P1/2	CC (43)
yk012 B-Cell Acute Lymphoblastic Leukemia	Excyte Biopharma Ltd	P1/2	CC (43)
Zilovertamab Vedotin B-Cell Acute Lymphoblastic Leukemia	Merck Sharp & Dohme LLC	P1/2	CC (43)
Apamistamab B-Cell Acute Lymphoblastic Leukemia	Memorial Sloan Kettering Cancer Center	Early P1	C (39)
Asciminib B-Cell Acute Lymphoblastic Leukemia	Marlise Luskin, MD	P1	C (39)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes B-Cell Acute Lymphoblastic Leukemia	City of Hope Medical Center	P1	C (39)
Azer-Cel B-Cell Acute Lymphoblastic Leukemia	Imugene Limited	P1	C (39)
cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes B-Cell Acute Lymphoblastic Leukemia	City of Hope Medical Center	P1	C (39)
cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes B-Cell Acute Lymphoblastic Leukemia	City of Hope Medical Center	P1	C (39)
cd19-car_lenti t cell B-Cell Acute Lymphoblastic Leukemia	Bambino Gesù Hospital and Research Institute	P1	C (39)
cd19x22 car t B-Cell Acute Lymphoblastic Leukemia	University of Colorado, Denver	P1	C (39)
Duocar20.19.22-D95 B-Cell Acute Lymphoblastic Leukemia	University of Kansas Medical Center	P1	C (39)
gt801 B-Cell Acute Lymphoblastic Leukemia	Grit Biotechnology	Early P1	C (39)
Humanized Cd19 Car-T Cells B-Cell Acute Lymphoblastic Leukemia	Zhujiang Hospital	Early P1	C (39)
jy231 B-Cell Acute Lymphoblastic Leukemia	Affiliated Hospital of Guangdong Medical University	Early P1	C (39)
Kite-753 B-Cell Acute Lymphoblastic Leukemia	M.D. Anderson Cancer Center	P1	C (39)
L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each) B-Cell Acute Lymphoblastic Leukemia	Stanford University	P1	C (39)
nkx019 B-Cell Acute Lymphoblastic Leukemia	Nkarta, Inc.	P1	C (39)
qh103 cell B-Cell Acute Lymphoblastic Leukemia	Anhui Provincial Hospital	P1	C (39)
qn-019a B-Cell Acute Lymphoblastic Leukemia	Zhejiang University	P1	C (39)
rd06-03 cell B-Cell Acute Lymphoblastic Leukemia	Anhui Provincial Hospital	Early P1	C (39)
Snuh-Cd19-Car-T B-Cell Acute Lymphoblastic Leukemia	Seoul National University Hospital	P1	C (39)
Stapuldencel B-Cell Acute Lymphoblastic Leukemia	Shenzhen Geno-Immune Medical Institute	P1	C (39)
vip943 B-Cell Acute Lymphoblastic Leukemia	Vincerx Pharma, Inc.	P1	C (39)
Hema-Neotil01 B-Cell Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	Early P1	C (36)
Human Cd19 Targeted Dash Car-T Cells B-Cell Acute Lymphoblastic Leukemia	Hrain Biotechnology Co., Ltd.	Early P1	C (36)
Metabolically Armed Cd19 Car-T Cells B-Cell Acute Lymphoblastic Leukemia	Anhui Provincial Hospital	Early P1	C (36)
Syncar-100 B-Cell Acute Lymphoblastic Leukemia	Zhejiang University	Early P1	C (36)
Tagraxofusp-Erzs B-Cell Acute Lymphoblastic Leukemia	M.D. Anderson Cancer Center	P1/2	C (33)
Autologous Human Peripheral Blood Lymphocytes (Primarily T-Cells, Expanded With Il-2, Cd3/Cd28 Beads) B-Cell Acute Lymphoblastic Leukemia	Beijing GoBroad Hospital	N/A	D (30)
Senl_B19 Autologous Car-T Treatment B-Cell Acute Lymphoblastic Leukemia	Peking University People's Hospital	N/A	D (30)
crc01 B-Cell Acute Lymphoblastic Leukemia	Curocell Inc.	P1/2	NR ()
gc019f B-Cell Acute Lymphoblastic Leukemia	Peking University Third Hospital	P1	NR ()
Talikabtagene Autoleucel B-Cell Acute Lymphoblastic Leukemia	Health Institutes of Turkey	P2/3	NR ()

Showing 101 to 136 of 136 assets

PreviousPage 3 of 3Next